Company Overview - Aspira Women's Health Inc. is focused on developing gynecologic disease diagnostic tools and has expanded its senior management team with the addition of Dr. Sandra Milligan as President effective April 1, 2024 [1][2] - The company has promoted Dr. Todd Pappas to lead the product development team following the departure of Dr. Jody Berry [1][4] Leadership Changes - Dr. Milligan brings over 25 years of experience in the healthcare sector, having held executive roles at biopharmaceutical companies such as Amgen, Genentech, Merck, and Organon [2] - As President, Dr. Milligan will oversee Research and Development, Operations, Information Technology, and Human Resources, with a focus on accelerating product launches and identifying partnerships [2][3] Product Development Focus - Dr. Pappas, who has been with Aspira since 2013, will continue to manage all aspects of scientific and product development, including relationships with academic partners [4] - The company is dedicated to enhancing outcomes for women suffering from gynecologic diseases, with a pipeline that includes advanced diagnostic tools for ovarian cancer and endometriosis [3][6] Diagnostic Tools and Pipeline - Aspira offers OvaWatch® and Ova1Plus® as part of the OvaSuiteSM, which provides comprehensive blood tests for ovarian cancer detection [5] - The company is developing OvaMDxSM and EndoCheckSM, aimed at improving noninvasive diagnostics for ovarian cancer and endometriosis, respectively [6]
Aspira Women's Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President